New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation.

Mithat Gunduz, Upendra A Argikar, Amanda L Cirello, Jennifer L Dumouchel
{"title":"New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation.","authors":"Mithat Gunduz,&nbsp;Upendra A Argikar,&nbsp;Amanda L Cirello,&nbsp;Jennifer L Dumouchel","doi":"10.2174/1872312812666180611113656","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic circulation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose major developability concerns. To date, multiple in vitro assays have been published to assess the risk associated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safety remains poor.</p><p><strong>Methods: </strong>In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as \"safe,\" \"warning,\" or \"withdrawn\" with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key intermediates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s).</p><p><strong>Results: </strong>Our results were in line with reported values in the literature. Our assay could be used in discovery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented.</p><p><strong>Conclusion: </strong>While the compounds tested from \"withdrawn\" and \"warning category\" all formed the glutathione adduct in buffer, none from \"safe\" category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative aldehyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest.</p>","PeriodicalId":11339,"journal":{"name":"Drug metabolism letters","volume":" ","pages":"84-92"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872312812666180611113656","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872312812666180611113656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Background: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic circulation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose major developability concerns. To date, multiple in vitro assays have been published to assess the risk associated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safety remains poor.

Methods: In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as "safe," "warning," or "withdrawn" with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key intermediates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s).

Results: Our results were in line with reported values in the literature. Our assay could be used in discovery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented.

Conclusion: While the compounds tested from "withdrawn" and "warning category" all formed the glutathione adduct in buffer, none from "safe" category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative aldehyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest.

Abstract Image

Abstract Image

Abstract Image

酰基葡糖苷类药物风险评估的新视角:体外稳定性、原位反应性和生物活性的研究。
背景:异种抗生素的酰基葡萄糖醛酸酯已成为制药行业广泛关注的主题,涉及生化反应性,肝脏处置和肠肝循环。作为临床候选药物,酰基葡萄糖醛酸盐的反应性和缺乏稳定性可能会引起主要的可发展性问题。迄今为止,已经发表了多个体外试验来评估酰基葡萄糖醛酸酯的相关风险。尽管如此,将这些发现转化为预测临床安全性仍然很差。方法:在本研究中,我们旨在提供简化的体外策略,以了解10种含羧酸的商业药物的酰基葡萄糖醛酸酯的生物活性潜力,这些药物在上市使用时被分类为“安全”、“警告”或“撤回”。酰基迁移是作为LC-MSn分析中观察到的峰数的函数来测量的。此外,我们对谷胱甘肽和甲氧基胺进行了反应性中间体捕获研究,分别确定了转酰基化生物激活途径和糖基化途径中的关键中间体。我们还利用重组udp -葡萄糖醛基转移酶(UGT) supersome®进行了反应表型分析,以研究酰基葡萄糖醛酸酯的形成是否与特定的UGT异构体有关。结果:我们的结果与文献报道值一致。我们的分析方法可用于发现研究,其中半衰期计算完全消除了化学合成酰基葡萄糖醛酸盐风险评估标准的需要。我们在流程图中捕获了风险评估的结果,以简化各种复杂的体外技术。结论:“撤检”和“警示”类化合物均在缓冲液中形成谷胱甘肽加合物,而“安全”类化合物均未形成谷胱甘肽加合物。相比之下,从任何类别测试的化合物都没有形成甲氧基胺缀合物,这是一种通过酰基迁移与假定的醛部分形成的反应。这些结果,高度支持亲核位移作为一个原因的反应性,而不是酰基迁移通过醛的形成。所提出的工作流程也可以应用于发现设置,以分类感兴趣的新化学实体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug metabolism letters
Drug metabolism letters Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
自引率
0.00%
发文量
12
期刊介绍: Drug Metabolism Letters publishes letters and research articles on major advances in all areas of drug metabolism and disposition. The emphasis is on publishing quality papers very rapidly by taking full advantage of the Internet technology both for the submission and review of manuscripts. The journal covers the following areas: In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信